For example, the deregulation of lysine methylation signaling has been shown to be a common pathogenic factor in cancers, making inhibitors of several histone lysine methyltransferases (KMTs) ideal chemotherapeutics.135 Among these KMTs, SET and MYND domain-containing protein 3 (SMYD3) was suggested to promote carcinogenesis in mouse models of PDAC via the methylation of MAP kinase MAP3K2 at lysine 260 and subsequently activate RAS signaling.135. Here, SMYD3 is linked to cancer.